Since its introduction last year, Australia’s ‘Amazon for cannabis’ has sold millions in medical cannabis products.
Burleigh Heads Cannabis (BHC), a subsidiary of CDA health, launched CanView in June 2020. The marketplace provides a place for pharmacists to order medical cannabis products from pharmaceutical companies in a centralised location.
Eight months after CanView’s launch, the platform has sold over $10 million in medical cannabis products. According to data from BHC, over 25% of Australian pharmacies are currently using CanView. Thousands of patients and 325 doctors are also using the platform.
CanView currently hosts over 80 medical cannabis products. As pharmacists would normally need to contact a medical cannabis company directly to order these, CanView streamlines the ordering process and ships medications. This has reduced the time it takes to facilitate a medical cannabis script from 10 days to 1-2 days.
According to BHC, CanView has only become more popular after CBD-oil was re-scheduled to an over-the-counter drug by the Therapeutic Goods Administration (TGA) in December.
In a statement from the company, pharmacist and Senior Partner at The Infinity Group (which owns Priceline) Milan Tappoo wrote that the change has “raised awareness” of medicinal cannabis and its benefits.
We witnessed a huge increase in demand and interest across all our stores since the TGA’s announcement… It’s driven people to their doctors to discuss prescription options.
Since June 2020, over 70,000 products have been shipped to patients through CanView. Over 21% of these were sent in February 2021 alone, reflecting a “recent surge” in medical cannabis use.
Figures from the TGA also show that record numbers of people (8,057 to be exact) were approved onto the Special Access Scheme in February this year. That’s a 125.8% increase from last year.
As the only platform of its kind in Australia, BHC expects CanView’s growth to continue throughout 2021.
